Fatty alcohol esters
Medchemexpress LLC AKN-028 acetate | 98.4% | 362.39 | 50 MG
AKN-028 acetate is a novel tyrosine kinase (TK) inhibitor. It is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. It inhibits FLT3 autophosphorylation and induces a dose-dependent cytotoxic response (mean IC50=1 μM). It also induces apoptosis by activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML).
- Novel tyrosine kinase (TK) inhibitor
- Potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM
- Inhibits FLT3 autophosphorylation
- Induces a dose-dependent cytotoxic response (mean IC50=1 μM)
- Induces apoptosis by activation of caspase 3
- Can be used in research of acute myeloid leukemia (AML)
- Inhibits growth of primary AML and MV4-11 cells in mice
Medchemexpress LLC AKN-028 acetate | 98.38% | 362.39 | 1 ML
AKN-028 acetate is a novel, potent, and orally active tyrosine kinase (TK) inhibitor. It specifically targets FMS-like receptor tyrosine kinase 3 (FLT3) with an IC50 value of 6 nM. This compound inhibits FLT3 autophosphorylation and induces a dose-dependent cytotoxic response. It also induces apoptosis through the activation of caspase 3, making it suitable for research in acute myeloid leukemia (AML).
- Potent and orally active tyrosine kinase inhibitor.
- Targets FLT3 with high specificity (IC50 = 6 nM).
- Induces dose-dependent cytotoxic response.
- Activates caspase 3, leading to apoptosis.
- Useful for acute myeloid leukemia (AML) research.
TARGETMOL CHEMICALS INC P505-15 ACETATE 5MG
Also available in 1 mg 10 mg 25 mg 50 mg 100 mg 500 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. P505-15 Acetate is a selective inhibitor of spleen tyrosine kinase that acts by suppressing leukocyte immune function and inflammation and leading to a reduction in arthritis score and attenuated histological damage. purity: 99%
Medchemexpress LLC Akn-028 (acetate) | 98.38% | 362.39 | 100 MG
AKN-028 acetate is a novel tyrosine kinase (TK) inhibitor. It is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. It inhibits FLT3 autophosphorylation and induces dose-dependent cytotoxic response (mean IC50=1 μM). AKN-028 acetate induces apoptosis by activation of caspase 3 and can be used in research of acute myeloid leukemia (AML).
- Potent and orally active FLT3 inhibitor with an IC50 of 6 nM.
- Inhibits FLT3 autophosphorylation.
- Induces dose-dependent cytotoxic response with a mean IC50 of 1 μM.
- Induces apoptosis through activation of caspase 3.
- Suitable for research in acute myeloid leukemia (AML).
- Shows cytotoxic activity against AML cell lines.
- Inhibits tumor growth in xenograft models.
Medchemexpress LLC AKN-028 (acetate) | 98.4% | 362.39 | 10 MG
AKN-028 acetate is a novel tyrosine kinase (TK) inhibitor and a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. It inhibits FLT3 autophosphorylation, induces dose-dependent cytotoxic response (mean IC50=1 μM), and triggers apoptosis by activating caspase 3. This compound is used in research of acute myeloid leukemia (AML).
- Potent, orally active FLT3 inhibitor (IC50 value of 6 nM)
- Inhibits FLT3 and KIT autophosphorylation
- Induces dose-dependent cytotoxic response (mean IC50=1 μM)
- Triggers apoptosis by activating caspase 3
- Effective in research models of acute myeloid leukemia (AML)
- Exhibits cytotoxic activity against AML cell lines
- Targets multiple kinases including CLK1, RPS6KA, VEGFR2, and FGFR2
Medchemexpress LLC 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(2-aminocyclohexylamino)pyrimidine-5-carboxamide acetate | 1370261-98-5 | MFCD23105961 | 99.8% | 453.50 | C21H27N9O3 | 10 MG
PRT062607 acetate is a research-grade small-molecule inhibitor of spleen tyrosine kinase (Syk), provided as a high-purity solid or as DMSO solutions for laboratory use. It is used in cellular and animal studies to probe Syk-mediated signaling, inflammation, and apoptosis pathways, and is supplied with analytical data to support research applications.
- Potent and selective Syk inhibition (IC50 ≈ 1 nM).
- High analytical purity (99.83%).
- Available as solid powder and 10 mM DMSO solutions for flexibility.
- Suitable for in vitro and in vivo preclinical studies.
- Supplied with supporting analytical documentation (COA/SDS).